DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

CAH·Cardinal Health, Inc.

$.
-. (-.%)
After Hours
High
$201.44
Open
$200.00
Market Cap
47.00B
52W High
$233.60
Low
$199.00
P. Close
$200.48
P/E
30.23
52W Low
$137.75
Fwd P/E
16.79
Mean Target
$245.27
Technical Score (1D)
32
SELL
News Sentiment
50
MIXED
Cardinal Health (CAH) shares have recently traded sideways, showing minimal movement over the past day and week. This recent flat performance follows an approximate 11% decline over the last three months, though one-year and multi-year total returns remain robust. Investors are currently evaluating the stock's valuation metrics against its substantial annual revenue and net income. The current sideways trading suggests a period of consolidation after prior gains, with the market assessing the company's longer-term momentum. Watch for any upcoming earnings reports or industry news that could provide a catalyst for a directional move.
Earnings Summary
Cardinal Health, Inc. is a global healthcare company operating in the Medical Distribution industry, a critical component of the broader Healthcare sector. The company specializes in distributing pharmaceuticals and medical products, offering a wide range of services including supply chain solutions and pharmacy management to healthcare providers and manufacturers. Its business is structured around two key segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution, underscoring its integral role in connecting the healthcare supply chain from manufacturers to end-users. Examining recent quarterly performance, Cardinal Health has demonstrated a generally positive trend in earnings per share (EPS) and revenue. In Q3 2025, the company reported an actual EPS of $2.55 against an estimate of $2.16845, and revenue of $64.009 billion. This followed a Q2 2025 where actual EPS was $2.08, exceeding the estimate of $2.03214, with revenue at $60.159 billion. Prior to this, Q1 2025 saw actual EPS of $2.35 against an estimate of $2.14886, and Q4 2024 reported actual EPS of $1.93 versus an estimate of $1.76425. The revenue data for the earlier quarters is not fully provided, but the trend suggests consistent EPS beats and significant revenue figures. Historically, Cardinal Health has shown a trajectory of year-over-year growth, with notable instances of exceeding analyst expectations for both earnings and revenue. The company has a pattern of delivering strong operational results, as evidenced by the Q3 2026 earnings where actual EPS of $3.17 surpassed the estimate of $2.8189, although reported revenue of $60.94 billion fell slightly short of the $62.29 billion estimate. This indicates a mixed performance in terms of revenue versus estimates in some periods, but a generally positive EPS beat rate. Recent news highlights a positive outlook from William Blair, which initiated coverage with an Outperform rating, suggesting confidence in Cardinal Health's strategic positioning. Furthermore, ahead of its fiscal third-quarter earnings report, analysts projected significant year-over-year growth in both EPS and revenue, driven by pharmaceutical demand and the performance of its Pharma and Specialty Solutions segment. Despite recent stock price underperformance relative to the broader market, the company is recognized for its value proposition with a favorable P/E ratio, and is actively pursuing higher-margin segments and expanding into community and outpatient settings for advanced therapies. Looking ahead, investors will be watching for confirmation of the anticipated growth drivers in the upcoming earnings reports, particularly how actual results compare to analyst expectations and the company's forward-looking guidance. Key will be the continued success in shifting the business mix towards higher-margin areas and the strategic execution of its expansion into new care settings, which are crucial for sustained profitability and market position.

EPS

EstBeatMiss
$1.55$2.01$2.47$2.92$3.38Q4'24Q1'25Q2'25Q3'25Q3'26
QtrEstActual+/−
Q3'26$2.82$3.17+12.5%
Q3'25$2.17$2.55+17.6%
Q2'25$2.03$2.08+2.4%
Q1'25$2.15$2.35+9.4%
Q4'24$1.76$1.93+9.4%

Revenue

EstBeatMiss
$53.5B$56.5B$59.4B$62.4B$65.4BQ4'24Q1'25Q2'25Q3'25Q3'26
QtrEstActual+/−
Q3'26$62.3B$60.9B-2.2%
Q3'25 - $64.0B -
Q2'25 - $60.2B -
Q1'25 - $54.9B -
Q4'24 - $55.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CAH Stock Snapshot

CAH is currently trading at $200.37, giving Cardinal Health, Inc. a market cap of 47.00B and a P/E ratio of 30.2. Today's range spans $199.00–$201.44, with shares opening at $200.00 and moving down $0.11 (0.1%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 50/100.

Over the past year CAH has traded between $137.75 and $233.60 - the current price is +45.5% off the 52-week low and -14.2% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $245.27 (range $215.00–$275.00), implying upside of +22.4%.

Cardinal Health, Inc. (CAH) is a large-cap in Healthcare with 47.00B in market cap, and the current technical read is bearish. Score: 32/100 (SELL). Sentiment: neutral at 50/100. Price: $200.37 (in the middle of its 52-week range). The current P/E ratio stands at 30.2. The 52-week range of $137.75–$233.60 provides the structural context, and the current SELL designation suggests that prior support levels are more important to watch than usual.

Analyst coverage for CAH becomes a double-edged factor in a SELL phase: at 47.00B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 32/100 technical reading and neutral sentiment (50/100) at $200.37 (in the middle of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $137.75–$233.60 range establishes where that repricing lands.